From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

HHS Awards Contract to Create Test to Identify Resistant Influenza Viruses

by Global Biodefense Staff
April 8, 2013

Technician Performing Diagnostics (HHS)The Department of Health and Human Services (HHS) last week announced a $1.8 million contract award to support development of a diagnostic test to identify antiviral resistance in influenza.

HHS states that rapid identification of antiviral resistance will lead to more effective treatment for patients.

The test is to be developed by Becton, Dickinson and Co., Franklin Lakes, N.J. The development work will be done over two years at BD Technologies, the technology development arm of BD, in Research Triangle Park, N.C.  

The test would combine detection of influenza virus with identification of antiviral drug resistance in clinical respiratory samples.  It will use a platform that combines the development of a test for identification of influenza antiviral resistance with a test cleared by the U.S. Food and Drug Administration for detection of influenza A and B, the most common human influenza viruses.

“Knowing that patients are infected with viruses that are resistant to antiviral drugs can help guide physicians to appropriate treatment and management for controlling the spread of influenza infections in health care facilities and communities,’’ said Robin Robinson, Ph.D., director of the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services. “This type of test, which could be performed easily in local laboratories, holds the potential to guide treatment options, helping to provide the best care to patients.”

The contract for advanced development is supported by BARDA, within the Office of the Assistant Secretary for Preparedness and Response.  The contract supports the development of a critical test that is part of a national pandemic preparedness strategy, which includes accelerating the advanced development of new methods for identifying antiviral drug resistance.

BARDA develops and procures medical countermeasures that address the public health and medical consequences of pandemic influenza and other emerging infectious diseases, and chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks.

Source: U.S. Department of Health and Human Services

From Our Partners
Tags: AntiviralsASPRAwardsBARDAChemical DetectionHHSInfluenza

Related Posts

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies
Biosurveillance

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
The Bioethics and Biosecurity Aspects of Targeted Wastewater Surveillance
Biosurveillance

The Bioethics and Biosecurity Aspects of Targeted Wastewater Surveillance

June 9, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC